| 0.3936 0 (0%) | 11-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.49  |
1-year : | 0.57 |
| Resists | First : | 0.42 |
Second : | 0.49 |
| Pivot price | 0.38 |
|||
| Supports | First : | 0.38 |
Second : | 0.36 |
| MAs | MA(5) : | 0.39 | MA(20) : | 0.38  |
| MA(100) : | 0.36 |
MA(250) : | 0.93 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.9 | D(3) : | 83.9 |
| RSI | RSI(14): 60 | |||
| 52-week | High : | 2.82 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AGTC ] has closed below upper band by 28.7%. Bollinger Bands are 77.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.39 - 0.4 | 0.4 - 0.4 |
| Low: | 0.39 - 0.39 | 0.39 - 0.39 |
| Close: | 0.39 - 0.39 | 0.39 - 0.4 |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Wed, 14 Jun 2023
Beacon Therapeutics enters gene therapy arena with $120m launch - Pharmaceutical Technology
Mon, 12 Jun 2023
Launch of Beacon Therapeutics with focus on gene therapies for retinal diseases - BioWorld Online
Mon, 12 Jun 2023
Syncona launches new gene therapy company Beacon Therapeutics - European Biotechnology News
Mon, 12 Jun 2023
Beacon of Light: Retinal Gene Therapy Developer Launches with $120M - Genetic Engineering & Biotechnology News
Mon, 12 Jun 2023
Syncona launches new gene therapy company Beacon Therapeutics - BioPharma-Reporter.com
Thu, 01 Dec 2022
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 6.063e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.466e+007 |
| EPS Est Next Qtrly | 0.02 |
| EPS Est This Year | -0.82 |
| EPS Est Next Year | -1.64 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -20 % |
| Return on Assets (ttm) | 361.5 % |
| Return on Equity (ttm) | -42.8 % |
| Qtrly Rev. Growth | 325000 % |
| Gross Profit (p.s.) | -22.16 |
| Sales Per Share | -75.7 |
| EBITDA (p.s.) | -1.35696e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.07 |
| Dividend | 0 |
| Forward Dividend | 2.1e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|